Tyra Biosciences (NASDAQ: TYRA) — Perfil da empresa, notícias e dados financeiros
Tyra Biosciences focuses on precision medicine to develop targeted therapies for cancer and genetic diseases.

Tyra Biosciences
Tyra Biosciences (NASDAQ:TYRA) focuses on driving scientific innovation to address critical needs in the treatment of cancer and other diseases through precision medicine. With a keen eye on the development of targeted therapies, Tyra Biosciences is steadfast in its mission to discover and develop novel compounds that can potentially transform patient outcomes. The company harnesses a unique research and development approach that prioritizes the understanding of the molecular and cellular fabric of diseases, aiming to bring forth solutions that are both innovative and effective. Their projects span across a broad spectrum of oncology and genetic diseases, aiming to unlock new treatment avenues and improve quality of life for patients. Objective-wise, Tyra Biosciences is dedicated to advancing its pipeline of therapies from early-stage discovery through to clinical development, with the ultimate goal of achieving regulatory approval and commercial success.
Resumo
Operações
Produtos e/ou serviços de Tyra Biosciences
- Development of precision oncology therapies targeting genetically defined vulnerabilities.
- Creation of small molecule drugs designed to overcome treatment resistance in cancer patients.
- Advancement of a robust drug discovery platform utilizing a proprietary structure-based drug design.
- Focus on therapy for FGFR (Fibroblast Growth Factor Receptor) mutations and fusions in various cancers.
- Involvement in collaborative research and development partnerships to enhance cancer treatment options.
- Provision of comprehensive biomarker and diagnostic strategies to personalize patient care.
equipe executiva do Tyra Biosciences
- Todd HarrisCo-Founder, CEO, President & Director
- Bhavesh AsharChief Operating Officer
- Douglas WarnerChief Medical Officer
- Daniel BensenCo-Founder & Chief Discovery Officer
- Alan FuhrmanChief Financial Officer
- Julia RuebVP of Finance & Principal Accounting Officer
- Robert L. HudkinsChief Technology Officer
- Ronald V. SwansonChief Scientific Officer
- Ali D. FawazGeneral Counsel & Secretary
- Sarah HonigSenior VP of Corporate Development & Strategy
Últimas notícias sobre a Tyra Biosciences
Principais indicadores financeiros
Resultados divulgados pela Tyra Biosciences, em USD.
- Cap. de mercado
- 1,5 bi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -2.4
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -132,8 mi | -119,9 mi | |
| 0 | -104,2 mi | -86,5 mi | |
| 0 | -79,9 mi | -69,1 mi | |
| 0 | -58,9 mi | -51,7 mi |